PBM Prosecution May Rely On Adverse Event From Rx Switch - FDLI Panel
Executive Summary
A serious adverse event associated with a therapeutic switch may be the trigger for a case to emerge from the ongoing Philadelphia grand jury investigation of PBM practices, panelists suggested during a Food & Drug Law Institute/Health Care Compliance Association meeting in Washington, D.C. Oct. 18.
You may also be interested in...
ADR Cases Could Be Prosecuted Under Kickback Statute – U.S. Atty Sheehan
The federal anti-kickback statute is broad enough to allow prosecution of pharmaceutical manufacturers for inadequate reporting of adverse events, Philadelphia Assistant U.S. Attorney James Sheehan maintained during a Food & Drug Law Institute meeting Sept. 12 in Washington, D.C
ADR Cases Could Be Prosecuted Under Kickback Statute – U.S. Atty Sheehan
The federal anti-kickback statute is broad enough to allow prosecution of pharmaceutical manufacturers for inadequate reporting of adverse events, Philadelphia Assistant U.S. Attorney James Sheehan maintained during a Food & Drug Law Institute meeting Sept. 12 in Washington, D.C
Allscripts Sees Potential Kickback Violation In Pharma-Funded e-Rx Devices
Pharmaceutical company-sponsored rollout of handheld prescription devices to physicians may invite prosecutorial scrutiny as part of ongoing investigations of inducements to physicians, Allscripts maintains.